Search Results

- The ESC M&PD meeting brings together the world’s experts working to improve the treatment of myocarditis and pericarditis. - Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass. - The Company will host a webcast conference call on December 1, 2025, to discuss the ARCHER findings and their significance, and to highlight the positive implications for Cardiol’s programs in inflammatory heart disease.

Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his position amid an ongoing probe into his “personal conduct”; FDA reverses course on approval requirements for uniQure’s Huntington’s gene therapy; Sarepta’s exon-skipping Duchenne muscular dystrophy drugs fail confirmatory study.

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

Explore how optimized DNA constructs drive more efficient, reproducible AAV production. You’ll learn: • How a 2-plasmid system reduces complexity • How ITR integrity impacts AAV yield and purity • Why Minicircle DNA enhances AAV production efficiency Speaker: Dr. Ram Shankar, Chief Scientific Officer, PlasmidFactory GmbH Date: Wed, Nov 19, 2025 Time: 17:00 CET / 16:00 GMT / 11:00 ET / 08:00 PT

Arena launched with $500 million in early 2024 to fund basic biological research, from which it planned to spin out dedicated companies to focus on drug development.

Harmony Biosciences has paused a mid-stage trial of ZYN002 in 22q11.2 deletion syndrome after the THC-free cannabinoid drug failed to significantly improve social avoidance in a late-stage study in fragile X Syndrome.